Beyond AirXAIR
XAIR
About: Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Employees: 107
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
190% more call options, than puts
Call options by funds: $29K | Put options by funds: $10K
14% more capital invested
Capital invested by funds: $6.57M [Q2] → $7.49M (+$920K) [Q3]
5.55% more ownership
Funds ownership: 26.64% [Q2] → 32.19% (+5.55%) [Q3]
33% less funds holding
Funds holding: 66 [Q2] → 44 (-22) [Q3]
65% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 17
81% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 27
Research analyst outlook
We haven’t received any recent analyst ratings for XAIR.
Financial journalist opinion
Based on 5 articles about XAIR published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products
In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative superiority safety claims for its iNO (inhaled nitric oxide) products or modify its advertising to avoid conveying the message that Beyond Air's products are safer than Vero's and/or that Vero's products are unsafe. In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative superiority safety claims for its iNO (inhaled nitric oxide) products or modify its advertising to avoid conveying the message that Beyond Air's products are safer than Vero's and/or that Vero's products are unsafe.
Neutral
Zacks Investment Research
1 week ago
Bears are Losing Control Over Beyond Air (XAIR), Here's Why It's a 'Buy' Now
Beyond Air (XAIR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
2 weeks ago
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Israeli Ministry of Health (IMOH) has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in combination with anti-PD-1 therapy. The trial will be conducted at four sites in Israel and patient screening will begin in the first quarter of 2025.
Neutral
GlobeNewsWire
2 weeks ago
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery
Neutral
GlobeNewsWire
3 weeks ago
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders
Neutral
GlobeNewsWire
1 month ago
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York.
Neutral
Seeking Alpha
1 month ago
Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2025 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Partners Marie Thibault - BTIG Yale Jen - Laidlaw & Company Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ending September 30, 2024. At this time, participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Beyond Air, Inc. (XAIR) Reports Q2 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11 th GARDEN CITY, N.Y.
Neutral
GlobeNewsWire
1 month ago
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes.
Charts implemented using Lightweight Charts™